Physician profile
Mitchell Meyerson
NPI 1205813268
$3,219.45
in general payments reported to CMS, 2019-2025
28 companies · $394 in 2025
The $394 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $428 · 2021: $422 · 2022: $508 · 2023: $237 · 2024: $88.89 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $260.66 | 2019-2025 | |
| Genentech USA, INC. | $257.53 | 2019-2021 | |
| Biofrontera INC. | $225.76 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $220.48 | 2019-2025 | |
| Leo Pharma INC. | $165.74 | 2019-2020 | |
| Lilly USA, LLC | $164.55 | 2019-2025 | Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $156.95 | 2019-2025 | Nemluvio, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $146.79 | 2019-2020 | |
| Genzyme Corporation | $144.63 | 2019-2023 | |
| Amgen INC. | $142.50 | 2021-2023 | Otezla |
| Incyte Corporation | $138.39 | 2022-2025 | Opzelura |
| Almirall LLC | $131.91 | 2019-2022 | |
| Dermira, INC. | $115.01 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $94.89 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $80.50 | 2019-2025 | Libtayo |
| Sandoz INC. | $62.60 | 2019 | |
| Pfizer INC. | $47.62 | 2019-2021 | |
| Celgene Corporation | $23.33 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $22.70 | 2019 | |
| Arcutis Biotherapeutics, INC. | $21.45 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $20.15 | 2025 | Ycanth |
| Janssen Biotech, INC. | $19.84 | 2022 | |
| Journey Medical Corporation | $19.61 | 2019 | |
| Aclaris Therapeutics, INC. | $18.91 | 2019 | |
| Dermavant Sciences, INC. | $17.93 | 2023 | Vtama |
| Strata Skin Sciences, INC. | $14.30 | 2020 | |
| Prugen, INC. Pharmaceuticals | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Meyerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.